The sugar industry, political authorities, and scientific institutions in the regulation of saccharin: Valencia (1888-1939).

In the late-nineteenth century food production and trade were greatly transformed. Changes in the food chain gave rise to new problems connected with food safety and food quality, which caused new controls to be introduced throughout Europe. In this paper I will contribute to ongoing debates by focusing on the regulation of saccharin in an agrarian city in the south of Europe, Valencia. The laboratory-made sweetener was introduced into the food market at the turn of the century, becoming highly controversial shortly afterwards. Several local groups of players got involved in this dispute. The sugar industry was not only an important stakeholder in the passing of some specific laws that were to constrain the use of saccharin, but also the main driver of regulation, primarily in periods when saccharin could become a serious competitor and reduce the sector's profit. Furthermore, the combined work of the sugar industry and the municipal laboratories was essential for the implementation of regulations. It was in such municipal laboratories that scientists played a main role in regulation. My paper will address the commercial disputes linked to the use of saccharin and the limited role of science and scientists in its control.

[Analysis of multi-component sugar aqueous solution in low-concentration by near-infrared spectrometry].

Near infrared spectrophotometry was used to determine the concentrations of one, two and three-component sugar aqueous solutions. However, this method was always applied to dry or low moisture products and was not practicable for fresh fruits and vegetables because of the strong absorption of water in near infrared region. In this paper, the authors applied NIR method to aqueous solutions and discussed how to enhance the sensitivity. In aqueous solution systems, concentration of each individual sugar was in range of 0.01-0.25 mol x L(-1). Different calibrations and predicted results were gotten and compared to each other when full spectra or significant spectra regions were considered. By selecting relevant spectra regions due to important structural information to overcome the disturbance from absorption of water, calculations could be optimized and predicted results of concentrations were more accurate regarding the standard error of calibration (SEC) and standard error of prediction (SEP).

Limitations in the use of ozone to disinfect maple sap.

The sap of the maple sugar tree (Acer saccharum) contains 2 to 3% sucrose and is traditionally collected early in the year and concentrated by boiling to produce maple syrup. High levels of microorganisms in the sap occur during holding, leading to a darker syrup with lower economic value. We investigated the use of dissolved ozone as a method to reduce the microbial population in sap. After 40 min of ozone treatment, concentrations of up to 0.30 mg/liter were achieved but were ineffective in reducing the aerobic plate count. Three predominant colonies on nutrient agar were selected for isolation and identification from sap. These included one mucoid and one nonmucoid yeast, both identified as Candida, and Pseudomonas fluorescens. When suspended in buffer, each was readily inactivated by ozone. Addition of 3% sucrose to the buffer markedly reduced the effectiveness of ozone. With the use of an ozone generator with a larger ozone output, saturating ozone concentrations (1 mg/liter) were achieved within 5 min but were accompanied by only a 1-log reduction in aerobic plate count of maple sap. After 40 min of ozone treatment, a less than 3-log reduction occurred. The results indicate that, because of the presence of sucrose, ozone may be of limited use in reducing the microbial population in sap.

Pharmacokinetics, prophylactic effects, and safety of a new recombinant FVIII formulated with sucrose (BAY 14-2222) in Japanese patients with hemophilia A.

A clinical trial of BAY 14-2222, a recombinant factor VIII preparation (rFVIII) manufactured by new purification and formulation processes using sucrose as a stabilizer instead of human serum albumin, was performed in 5 previously treated Japanese patients with severe hemophilia A. In stage I, a single dose of BAY 14-2222 and Kogenate (a currently licensed rFVIII preparation) was administered alternately in the same patients to compare the pharmacokinetics of the 2 compounds using FVIII:C (FVIII clotting activity) as the measure of plasma drug levels. The normalized area under the curve (AUCnorm) and normalized maximal concentration (Cmax,norm) were slightly lower following the administration of BAY 14-2222 than those after the administration of Kogenate (ratio of BAY 14-2222/Kogenate:AUCnorm = 0.88, P = .050; and Cmax,norm = 0.87, P = .041). However, the biological half-life (t1/2) did not differ significantly between the 2 preparations (13.96 +/- 4.18 vs. 13.48 +/- 2.40 hours). The in vivo recovery of FVIII was 67.9 +/- 11.3% after the administration of BAY 14-2222 and 74.4 +/- 5.3% after the administration of Kogenate. In stage II, BAY 14-2222 was administered regularly to the 5 patients with hemophilia at single doses of 20 to 40 IU/kg 3 times weekly for 4 weeks, and its prophylactic effect on bleeding was evaluated. Results indicated that BAY 14-2222 has a good preventive effect on bleeding. Sixty-six infusions were performed in stages I and II of this trial, and no adverse reactions related to BAY 14-2222 were observed. In addition, there were no FVIII inhibitors or antibodies to foreign proteins detected. The trial confirmed that BAY 14-2222 is similar to Kogenate with respect to t1/2 and the in vivo recovery of FVIII:C and that periodic infusions for 4 weeks can be well tolerated. In addition, it was shown that BAY 14-2222 is effective in preventing bleeding. Thus it is expected that BAY 14-2222 will exhibit a hemostatic effect comparable to that of Kogenate in patients with hemophilia A.

Overview of olestra: a new fat substitute.

Olestra is a mixture of hexa-, hepta- and octa-esters formed from the reaction of sucrase and long chain fatty acids isolated from edible oils. Olestra has properties similar to those of traditional triglycerides but is not hydrolyzed by pancreatic lipases and, therefore, serves as a noncaloric replacement for fats in the diet. The safety of olestra has been established in over 100 studies in seven different species of animals, with confirmatory safety data coming from approximately 75 human studies; consumption of olestra at levels typical for savoury snacks does not result in reports of gastrointestinal problems in humans. This is consistent with the results of studies of the physiological and morphological effects of olestra in animals and in humans. It is anticipated that olestra will be available in Canada in the near future. Patients will soon be asking their physicians about its use. This article provides an overview of olestra.

Effects of radiochemical impurities on measurements of transfer constants for [14C]sucrose permeation of normal and injured blood-brain barrier of rats.

Radiolabeled sucrose is often used to assess blood-brain barrier (BBB) injury in the rat, but published transfer constants (K[i]s) for sucrose permeation of the intact BBB (control K[i]s) are highly discrepant. A potential problem with the commonly used tracer, [14C(U)]sucrose, is radiolytic generation, preuse, of radiocontaminants that might readily penetrate the BBB. How such contaminants might affect measurements of sucrose K(i)s was examined for both the intact and the ischemically injured BBB. Three stocks of [14C(U)]sucrose were studied: newly purchased ("new"), 4-year-old, and 7-year-old. A high purity (99.9%) "new" and a 2-year-old stock of [3H(fructose-1)]sucrose were also tested. Pentobarbital-anesthetized male Sprague-Dawley rats were injected i.v. with each tracer separately (six to eight rats) and K(i)s in five brain regions were measured by the multiple-time graphical method. The "new" 14C-, "new" 3H-, and 2-year-old 3H-sucrose yielded comparable K(i)s , ranging from 1.2 +/- 0.1 to 2.4 +/- 0.3 nl x g(-1) x s(-1) (mean +/- SE) across the regions. The two old stocks of 14C-sucrose yielded significantly higher regional K(i)s : 5.1-6.3 (4-year-old) and 8.4-9.7 (7-year-old). Thin-layer chromatography of the three 14C-tracers revealed that each contained radioimpurities (ca. 2% in both the "new" and 4-year-old, and 9% in the 7-year-old), but that the old stocks contained larger amounts of relatively mobile (more lipophilic) impurities, which can be suspected as the main cause of the elevated K(i)s obtained. Additional rats were subjected to 10 min of cerebral ischemia, which effects a delayed BBB injury, and 6 h later the "new" 3H- and the 4-year-old 14C-sucrose were injected together. The K(i)s for both tracers were elevated by like, absolute amounts (deltaK[i]s), but by very different percentages, over their disparate baseline values in uninjured rats (for striatum and hippocampus, the most injured regions, deltaK(i)s were 3.9 to 4.4 nl x g[-1] x s[-1]). It is concluded that radiolysis of [14C(U)]sucrose yields certain labeled products that readily cross the BBB and that can seriously distort baseline K(i)s , even if present only in very small amounts. While this appears not to compromise assessment of BBB injury, definition of the authentic range of baseline, sucrose K(i)s for the rat BBB would appear to remain a challenge.

[Potassium Sucrose Octa Sulfate Reference Standard (Control 961) of National Institute of Health Sciences].

The raw material of potassium sucrose octa sulfate was examined for the preparation of the "Potassium Sucrose Octa Sulfate Reference Standard (Control 961)". Analytical data obtained were as follows: infrared spectrum, the same as that of the Potassium Sucrose Octa Sulfate Reference Standard (Control 901); high-performance liquid chromatography, one impurity was detected; water content, 8.1%; assay of sucrose octa sulfate, 99.6%. Based on the above results, the raw material was authorized to be the Potassium Sucrose Octa Sulfate Reference Standard of the National Institute of Health Sciences.

[Potassium Sucrose Octa Sulfate Reference Standard (Control 901) of National Institute of Hygienic Sciences].

The raw material of potassium sucrose octa sulfate was examined for the preparation of the "Potassium sucrose octa sulfate Reference Standard (Control 901)". Analytical data obtained were as follows: infrared spectrum, 3494, 1642, 1247, 1002, 795, 584 cm-1; high-performance liquid chromatography, 3 impurities were detected; water, 6.2%; assay of sucrose octa sulfate, 99.1%. Based on the above results, this raw material was authorized to be the Reference Standard of the National Institute of Hygienic Sciences.